Bluejay Diagnostics released preliminary clinical data from the SYMON-II study supporting the Symphony IL-6 test's potential for mortality risk assessment in sepsis, marking a key milestone toward regulatory submission.
Bluejay Diagnostics released preliminary clinical data from the SYMON-II study supporting the Symphony IL-6 test's potential for mortality risk assessment in sepsis, marking a key milestone toward regulatory submission.